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Abstract 
Background: Advances in surgical technique, prosthetic heart valve design and 
anticoagulation have contributed to an overall improvement in morbidity and mortality in 
women with heart valve prostheses, as well as increased feasibility of pregnancy.  Previous 
work investigating the pregnancies of women with prosthetic valves has been largely directed 
towards understanding the influence of anticoagulation regimen.  There has been little 
investigation on maternal and infant outcomes.  The objective of this systematic review will 
be to assess the outcomes of pregnancy in women with heart valve prostheses in 
contemporary populations.   
Methods and design:  A systematic search of Medline, Embase, CINAHL and The Cochrane 
Library will be undertaken.  Article titles and abstracts will be evaluated by two reviewers for 
potential relevance.  Studies that include pregnancies occurring from 1995 onwards and 
where there are six or more pregnancies in women with heart valve prostheses included in the 
study population will be reviewed for potential inclusion.  Primary outcomes of interest will 
be mortality (maternal and perinatal).  Secondary outcomes will include other pregnancy 
outcomes.  No language restrictions will be applied.  Methodological quality and 
heterogeneity of studies will be assessed.  Data extraction from identified articles will be 
undertaken by two independent reviewers using a uniform template.  Meta-analyses will be 
performed to ascertain risk of adverse events and where sufficient numbers by type of 
prosthesis and location as well as other subgroup analyses. 
Discussion: Estimates of the risk of adverse events in recent pregnancies of women with heart 
valve prosthesis will provide better information for counselling and decision-making.  Given 
the improvements in prognosis of heart valve prosthesis recipients and the paucity of 
definitive data regarding optimal pregnancy management for these women, review of this 
topic is pertinent. 
Review registration: This protocol has been registered with the international prospective 
register of systematic reviews (PROSPERO), number: CRD42013006187 
Keywords: Pregnancy, heart valve prosthesis, cardiovascular diseases, perinatal 
mortality 
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Background 
The aetiology of valvular heart disease and management of congenital heart disease in young 
women continues to change.  Advances in surgical technique, prosthetic heart valve design 
and anticoagulation have contributed to an overall improvement in morbidity and mortality 
[1-4].  The number of women with heart valve prostheses counselled explicitly against 
pregnancy is decreasing with improvement in understanding of what conditions and cardiac 
parameters constitute high risk of adverse events during pregnancy [5, 6].  The focus is 
shifting to provision of informed decision-making around the risk pregnancy might place on 
women and their babies.  With these changes in mind, understanding the outcomes of 
pregnancies in women who have heart valve prostheses in the contemporary setting is of 
increasing relevance. 
During normal pregnancy there is an increase in haemodynamic load, which continues to rise 
during labour.  This is as a result of increases in stroke volume and heart rate, increasing 
cardiac output by an estimated 30-40%, combined with a decrease in total peripheral 
resistance, leading to a decrease in blood pressure [7-9].  Pregnancy is a pro-coagulant state 
due to an elevation in circulating pro-coagulant factors and maternal hormones, leading to a 
decrease in prothrombin time, activated partial thromboplastin time, thrombin time and 
international normalized ratio (INR) [10, 11].  Tolerance of these haemodynamic and 
coagulatory changes in women with pre-existing heart disease, including those with 
bioprosthetic and mechanical heart valve prostheses, is known to vary with underlying 
cardiac function and aetiology of cardiac disease [6]. 
Previous work surrounding heart valve prostheses in pregnancy has been largely directed 
towards understanding the influence of anticoagulation type in the setting of mechanical heart 
valve prostheses [12-16].  A systematic review published in 2000, including 976 women who 
had 1234 pregnancies, focused on maternal and fetal complications associated with various 
anticoagulation regimens [17].  The review included studies with pregnancies occurring from 
1966-1997.  As such, a large number of study participants (433/976) had older generation and 
more thrombogenic cage-and-ball heart valve prostheses.  Pooled analysis from this work 
demonstrated higher rates of fetal malformation in those women treated with oral 
anticoagulation in the first trimester (6.4% [CI 95% 4.6-8.9] of pregnancies), as compared to 
where heparin was used in the first trimester (3.4% [CI 95% 1.4-7.7] of pregnancies) [17].   A 
higher risk of thromboembolic complications was noted with heparin use.  Another more 
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recent review (2011) using pooled data from 959 pregnancies receiving oral anticoagulation 
throughout pregnancy and 285 pregnancies receiving unfractionated heparin in the first 
trimester found an incidence of maternal thromboembolic complications in 3.9% and 9.5% of 
pregnancies in each group respectively [18].   
In the setting of mechanical heart valve prostheses in pregnancy, there is consensus in current 
international guidelines that one of three anticoagulation regimens may be used following 
assessment of maternal risk factors and preference: oral anticoagulation throughout 
pregnancy, oral anticoagulation with replacement by low molecular weight heparin or 
unfractionated heparin during weeks 6-12, or low molecular weight heparin or unfractionated 
heparin throughout pregnancy.  Each of these regimens requires counseling around risk and 
judicious monitoring throughout, including INR and anti-factor Xa levels where applicable 
[5, 19, 20].  The Royal College of Obstetricians recommends women are offered a choice of 
one of these three regimens with education around the risks and benefits of each [21]. 
Bioprosthetic heart valves avoid the need for anticoagulation during pregnancy [20, 22].   
However, their use in younger patients has previously been limited due to the increased need 
for re-replacement compared to their mechanical counterparts [23, 24].  This has been 
demonstrated in young women specifically, with 82% (CI 95% 62-92) of women with 
bioprosthetic valve prostheses requiring replacement at ten years as opposed to only 29% (CI 
95% 17-39) of women with mechanical valves [23].  Despite initial suggestions, recent work 
has not shown an increase in the rate of bioprosthetic valve deterioration in women 
undertaking pregnancies as opposed to women who do not [25, 26].  With decreasing 
mortality and morbidity associated with valve re-replacement, international guidelines 
suggest that bioprosthetic valves should be considered when heart valve replacement is 
required in women who may wish to become pregnant [5, 27]. 
Little work has been done exploring the population of contemporary heart valve recipients 
undertaking pregnancy.  Specifically, other than anticoagulant type [12-18], there has been 
little investigation around rates and risk factors for maternal and infant adverse events.  Given 
the changes in heart valves used, improvement in prognosis of contemporary heart valve 
prosthesis recipients and the paucity of data in regarding the outcomes of pregnancies in these 
women, review of the studies in this area is warranted. 
Objectives 
  Prosthetic heart valves in pregnancy SR  
 
Page 5 of 16 
 
Primary: To assess the risks of adverse outcomes of pregnancy among women with a 
prosthetic heart valve(s) in the contemporary setting. 
Secondary: To assess the risks and relative risks of adverse outcomes of pregnancy in women 
with a prosthetic heart valve(s) by prosthesis type and/or location. 
Methods and design 
Study registration 
This protocol has been registered with the international prospective register of systematic 
reviews (PROSPERO), number CRD42013006187 
 
The systematic review protocol has been conducted and reported using the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [28] where 
applicable and the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) 
reporting guidelines [29]. 
Outcomes of interest 
Primary outcomes: 
1) Maternal mortality 
2) Any pregnancy loss 
a. Any loss of pregnancy including miscarriage/stillbirth/termination of 
pregnancy [30]  (or as defined by study) 
3) Perinatal mortality [30] 
a. Stillbirth:  Fetal death in utero ≥ 22 weeks gestation [30] (or as defined by 
the study) 
b. Neonatal mortality: Death in the first 28 days of extra-uterine life [30] 
c. Perinatal mortality: Stillbirth or neonatal mortality 
Secondary outcomes: 
1) Adverse maternal outcomes  
a. Any thromboembolic events including 
i. Stroke/Transient ischaemic event (TIA) 
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ii. Valve thrombosis 
iii. Other 
b. Any obstetric haemorrhage including 
i. Antenatal haemorrhage 
ii. Postpartum haemorrhage 
c. Cardiovascular compromise (as defined by study) 
d. Valve deterioration (bioprosthetic valves only, as defined by study) 
e. New arrhythmia 
f. Infective endocarditis 
g. Myocardial infarction 
h. Pregnancy hypertension including gestational hypertension, pre-eclampsia 
and eclampsia 
2) Labour and delivery outcomes (including those subject to clinical decision 
making) 
a. Mode of delivery 
3) Adverse birth outcomes 
a. Preterm birth 
Delivery before 37 weeks of gestation 
b. Small for gestational age (SGA) 
Less than tenth birth weight percentile for sex and gestational age 
c. Low birth weight (LBW) 
Birth weight less than 2 500 grams 
d. Infant admission to Neonatal Intensive Care Unit (NICU) 
e. Congenital malformation 
 
Search strategy for identification of studies and methods of review 
A systematic search of Medline, Embase, Cumulative Index to Nursing and Allied Health 
Literature (CINAHL) and The Cochrane Library will be undertaken to identify relevant 
studies published between 1995 and May 2013.  Search terms will include “pregnancy” AND 
(“heart valves” OR “heart valve replacement” OR “heart valve prosthesis” OR “heart valve 
prosthesis implantation”).  The “explode” function will be used in each case.  Searches will 
be limited to studies of humans and peer-reviewed articles.  Language restrictions will not be 
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applied and every effort will be made to obtain translations; articles unable to be translated 
will be reported.  Duplicates will be removed. 
Eligibility criteria for consideration of inclusion 
Study types:  
Studies that report outcomes of women with prosthetic valves undertaking pregnancy: 
• Randomised controlled trials 
• Clinical trials 
• Cohort studies 
• Cross-sectional studies 
• Unselected case series 
Studies that compare outcomes for women with prosthetic valves by valve location or 
type: 
• Randomised controlled trials 
• Clinical trials 
• Cohort studies 
• Case-control studies 
Control or comparison groups are not necessary to the primary objective of estimating risk 
among women with valve prosthesis. It is anticipated that most of the studies identified for 
consideration will be case series.  
Populations: Populations of pregnant women that include women with prosthetic heart 
valves. 
Comparators: 
Where studies differentiate between mechanical and biological valve prosthesis, or between 
valve location (i.e. mitral, aortic, pulmonary, tricuspid), applicable to the secondary 
objective; relative risks by prosthesis type and/or location, relative risks of adverse events 
will be calculated using: 
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• Biological prosthesis as the denominator for calculating relative risk compared to 
mechanical 
• Presence of mitral valve prosthesis as the denominator for calculating relative risk 
compared to other valve locations 
Study criteria: 
• Include pregnancies occurring from 1995 onwards only 
• Contain at least six pregnancies in women with heart valve prostheses in the study 
population.  This was chosen as it has been used in a systematic review exploring 
anticoagulation regimens during pregnancy in women with heart valve prostheses 
[17]. 
• Study population should have fewer than 5% of women with a Starr-Edwards (cage-
and-ball) heart valve prosthesis.  This was a pragmatic decision.  Cage-and-ball are 
no longer implanted due to high thrombogenic complication rates [31, 32], and 
therefore not relevant when evaluating in the contemporary setting.  Consequently, 
where the study population consists of 20 or less women, if one (5%) or more 
participants has a cage-and-ball valve the study will be excluded. 
• Where a case series is presented, participants have not been selected due to the 
occurrence of an adverse event (e.g. valve thrombosis during pregnancy) 
• Not a conference abstract and unpublished study. 
Exposure of interest: Pregnancy in women with a heart valve prosthesis 
Screening of studies 
Article titles and abstracts will be evaluated by two reviewers for potential relevance. Where 
there is disagreement at this stage, the article will remain included until the full text is 
reviewed prior to a decision being made. Exclusions at this stage will include those articles 
relating to heart valves but either not replacement or not in pregnancy, related to the heart but 
not specifically valvular disease, related to the fetal/infant heart or basic science.  Articles 
identified through reference lists of included studies and relevant systematic reviews will be 
considered for inclusion based on their title. 
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At least two independent reviewers will assess all articles identified in the screening process 
for potential inclusion, including assessment of methodological quality as outlined below.  
Where information pertinent to inclusion criteria is not contained within the article text, effort 
will be made to contact the listed corresponding author.  Where no reply is received, the 
article will be excluded.  Consensus between the two authors undertaking review of the study 
will need to be reached before the article is included.  In the case that a consensus is not 
reached, a third reviewer will be involved as an arbitrator.  A flow chart of the study selection 
procedure will be prepared and a log of rejected studies maintained. 
Data extraction 
Data extraction from identified articles will be undertaken by two independent reviewers 
using a uniform template.  Discrepancies will be resolved by discussion, and where 
applicable, arbitration by a third reviewer. 
The following information will be extracted: 
Study characteristics: Authors, year of publication, study design, location, time period 
of included pregnancies  
Population characteristics: Number of participants, number of pregnancies, maternal 
age, parity 
Heart valve characteristics: Number of mechanical valves, number of bioprosthetic 
valves, implanted valve type, implanted valve location, anticoagulation regimen 
Adverse outcomes: Frequency of adverse outcomes as outlined above 
Assessment of methodological quality 
It is thought likely that the only randomised studies eligible for inclusion will be randomised 
control trials assessing different valve types.  The risk of bias in randomised studies will be 
assessed using the Cochrane Collaboration’s tool for assessing risk of bias [33].  This tool 
provides a model to evaluate the risk of bias across a number of domains; how a study selects 
participants, measures performance, blinds participants and investigators, explores attrition 
and reports findings. Each domain for each study will be allocated a ranking of “low”, 
  Prosthetic heart valves in pregnancy SR  
 
Page 10 of 16 
 
“unclear” or “high” risk of bias, in accordance with the Cochrane Collaboration’s approach 
by two separate reviewers.  Where there is a discrepancy between the two reviewers, a third 
reviewer will be used as an arbitrator. 
Included non-randomised studies may or may not have a comparison group.  To assess the 
risk of bias within included  these studies, the methodological quality of potential studies will 
be assessed using the Newcastle–Ottawa scale (NOS) for assessing the quality of non-
randomised studies in meta-analyses [34].  The NOS for case-control and cohort studies will 
be adapted (Table 1) to meet the specific needs of this systematic review.  The cohort scale 
will be modified for use in case series [34].  Using the NOS, studies will be awarded a 
maximum of nine points on items related to the selection of the study groups, the 
comparability of the groups and the ascertainment of outcome of interest.  Using this 
modified score; case series will be eligible for a maximum of six points.  This will be 
undertaken by two separate reviewers.  Where there is disagreement, a third reviewer will be 
used as an arbitrator.  
Data analysis and presentation 
A table with descriptive information for each study will be produced (Table 2).  From 
extracted data, the risk of outcomes for the primary objective will be calculated by dividing 
the total number of outcome occurrences by the total number of pregnancies or births to 
women with a heart valve prosthesis.  The risk of maternal mortality and any pregnancy loss 
will be expressed as the proportion of the total number of pregnancies (including 
miscarriages, terminations, stillbirths and livebirths).  The risk of perinatal death and 
secondary adverse birth outcomes (as opposed to pregnancy outcomes) will be expressed as a 
proportion of the pregnancies beyond 22 weeks gestation or 500 grams or resulting in a live 
birth [30].  It is anticipated that these denominators may not always be clearly articulated, 
potentially constraining the process to what is reported in each study. 
Subgroup analysis of primary and secondary outcome relative risks by valve location and 
valve type will be undertaken if reported by at least two studies, each with at least six or more 
pregnancies in the subgroup.  Comprehensive Meta Analysis (Version 2.0) software will be 
used for the data analysis.  This software enables pooling of risks, as well as of relative risks, 
making it suitable for our primary objective, especially as it is anticipated that the majority of 
studies will be case series.   Pooled risks will be calculated using a random effects model, 
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with variance calculated using a logit conversion.  Graphic summaries of individual study 
estimates and overall estimates will be produced.  Statistical uncertainty will be assessed 
using 95% confidence intervals around risk estimates. 
Where applicable, heterogeneity of effect for studies within a meta-analysis will be assessed 
with the I2 statistic.  Study heterogeneity will be explored by categorisation of the study 
design, the year of publication, the time period within which pregnancies occur and 
population characteristics (ethnicity, age range, aetiology of underlying disease, type and 
location of heart valve prosthesis, anticoagulant regimen).  It is expected that study 
characteristics will vary and that random effects models will be appropriate for estimating 
overall event risks.  
In general, the strength of evidence will be assessed with respect to the study designs, the 
methodological quality of the individual studies, the consistency of the results across studies 
and, for studies with a comparison or control  group, the strength of associations. More 
specifically, given the likelihood that most studies will be uncontrolled case series, the 
strength of evidence will be assessed primarily by the width of the confidence interval around 
pooled outcome rates. Consistency of effect will also be important both as demonstrated 
visually in the plots and as quantified by the I2 statistic. 
Discussion 
Improved care for chronic diseases and delayed age of childbearing has contributed to an 
increase in the number of pregnant women with concurrent medical conditions including 
valvular heart disease.  The proposed systematic review is of importance in the context of 
global pressure to improve maternal and infant health, including the evaluation of 
pregnancies in subgroups of women with co-morbidities.  In Australia this is seen through the 
prioritisation of research work encompassing “Healthy start to life for all Australians” [21]. 
Meta-analyses of observational studies present challenges because of inherent biases within 
different study designs [35].  Nevertheless they help understanding and quantify variation in 
results between studies [29].  In the context of predominantly observational studies, it is thus 
essential that a rigorous protocol be designed to address the outcome of pregnancies in 
women with heart valve prostheses. 
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Through exploration of the outcomes of pregnancies in women with heart valve prosthesis in 
the contemporary setting (1995 onwards) this systematic review will provide estimates of the 
risk of adverse events in these pregnancies.  It is hoped that this information will improve the 
understanding of risk factors for poor maternal, pregnancy and infant outcomes, thereby 
providing information for clinical decision-making and patient counselling.  It is timely that 
this work is undertaken given the developments in heart valve prosthesis technology, overall 
improvement in prognosis of young women with a heart valve prosthesis and increasing in 
number of women with congenital heart disease reaching reproductive age. 
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Table 1. Adapted NOS [34] for “Prosthetic heart valves in pregnancy: A systematic review 
and meta-analysis protocol” 
 
Criteria Star allocated 
(Maximum 9 
stars)* 
Selection 
1) Representativeness of the exposed cohort 
a) Population truly representative of pregnant women with prosthetic heart valves � 
b) Somewhat representative of the population of pregnant women with prosthetic 
heart valves 
� 
c) Selected group of users e.g. referral hospital patients - 
d) No description of the derivation of the cohort - 
2) Selection of the non-exposed cohort † 
a) Drawn from the same community as the exposed cohort � 
b) Drawn from a different source - 
c) No description of the derivation of the non-exposed cohort - 
d) Not applicable - 
3) Ascertainment of exposure 
a) Secure record (e.g. medical records) � 
b) Structured interview � 
c) Written self-report - 
d) No description - 
4) Demonstration that outcome of interest was not present at start of study ‡ 
a) Yes � 
b) No - 
c) Not applicable - 
Comparability 
Comparability of cohorts on the basis of the design or analysis 
a) Study controls for maternal age (select the most important factor) � 
b) Study controls for any additional factor (type of valve, valve location, 
anticoagulation regimen) 
� 
c) Not applicable - 
Outcome 
1) Assessment of outcome 
a) Independent blind assessment � 
b) Record linkage � 
c) Self-report - 
d) No description - 
2) Was follow-up long enough for outcomes (as defined by study) to occur 
a) Yes � 
b) No - 
3) Adequacy of follow up of cohorts 
a) Complete follow up (all subjects accounted for and no missing data) � 
b) Subjects lost to follow up unlikely to introduce bias - small number lost - ≥ 80%  � 
c) Follow up rate < 80%  - 
d) No statement - 
* A study can be awarded a maximum of one star for each numbered item within the selection and outcome 
categories. A maximum of two stars can be given for comparability 
† For example, women without a heart valve prosthesis undertaking pregnancy.  Likely to be “not applicable” 
for some study types including case-series 
‡ Suggested primary outcomes: Maternal mortality, any pregnancy loss, perinatal mortality 
  Prosthetic heart valves in pregnancy SR  
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Table 2.  Sample of table to record descriptive information extracted from each included study 
Study Subgroup 
N
um
be
r 
of
 w
om
en
 v
al
ve
 p
ro
st
he
se
s 
N
um
be
r 
of
 p
re
gn
an
ci
es
 
N
um
be
r 
pr
eg
na
nc
ie
s >
22
 w
ee
ks
  
M
at
er
na
l m
or
ta
lit
y 
(n
) 
A
ny
 p
re
gn
an
cy
 lo
ss
 (n
) 
Pe
ri
na
ta
l m
or
ta
lit
y 
(n
) 
M
isc
ar
ri
ag
e 
(n
) 
Te
rm
in
at
io
n 
of
 p
re
gn
an
cy
 (n
) 
St
ill
bi
rt
h 
(n
) 
N
eo
na
ta
l d
ea
th
 (n
) 
Li
ve
bi
rt
h 
(n
) 
Pr
et
er
m
 b
ir
th
 (n
) 
Sm
al
l f
or
 g
es
ta
tio
na
l a
ge
 (n
) 
Lo
w
 b
ir
th
 w
ei
gh
t (
n)
 
In
fa
nt
 a
dm
is
sio
n 
to
 N
IC
U
 (n
) 
C
on
ge
ni
ta
l m
al
fo
rm
at
io
n 
(n
) 
A
ny
 th
ro
m
bo
em
bo
lic
 e
ve
nt
 (n
) 
Is
ch
ae
m
ic
 st
ok
e/
T
IA
 (n
) 
V
al
ve
 th
ro
m
bo
sis
 (n
) 
O
th
er
 (n
) 
A
ny
 o
bs
te
tr
ic
 h
ae
m
or
rh
ag
e 
(n
) 
A
nt
en
at
al
 h
ae
m
or
rh
ag
e 
(n
) 
Po
st
pa
rt
um
 h
ae
m
or
rh
ag
e 
(n
) 
C
ar
di
ov
as
cu
la
r 
co
m
pr
om
ise
 (n
) 
V
al
ve
 d
et
er
io
ra
tio
n 
(n
) 
N
ew
 a
rr
hy
th
m
ia
 (n
) 
In
fe
ct
iv
e 
en
do
ca
rd
iti
s (
n)
 
M
yo
ca
rd
ia
l i
nf
ar
ct
io
n 
(n
) 
Pr
eg
na
nc
y 
hy
pe
rt
en
sio
n 
(n
) 
Sp
on
ta
ne
ou
s v
ag
in
al
 d
el
iv
er
y 
(n
) 
In
st
ru
m
en
ta
l v
ag
in
al
 d
el
iv
er
y 
(n
) 
Pr
e-
la
bo
ur
 c
ae
sa
re
an
 se
ct
io
n 
(n
) 
In
tr
ap
ar
tu
m
 c
ae
sa
re
an
 se
ct
io
n 
(n
) 
“A” All*                                  
 Study A, 
subgroup 1† 
                                 
 Study A 
subgroup 2 ‡ 
                                 
…                                   
 
* All pregnancies to women included in the study 
† e.g. pregnancies to women with a mechanical prosthesis in study A 
‡ e.g. pregnancies to women with a bioprosthesis in study A 
